Monday, 19 February 2018 - 8:31
  • it
  • de
  • en
  • fr

Trials

Positive Phase III results for Ipsen’s liver cancer therapy, shares soar

Ipsen and its partner Exelixis have announced they have interrupted the Phase III Celestial clinical trial, since the investigational therapy Cabometyx (cabozantinib) has reached its endpoints earlier than expected. Specifically, Cabometyx has been reported to provide a statistically significant improvement…

Roche granted approval for ocrelizumab (multiple sclerosis) in Europe

Roche has announced that the European Commission has granted a marketing authorization to ocrelizumab, for the treatment of patients with relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. The European Commission has considered the positive results from the…

CRISPR technology for the treatment of deafness with genetic causes

The journal Nature has published an article reporting a new, significant success of CRISPR technology–Cas9. A team of researchers led by David R. Liu, at Rice University of Houston has succeeded in correcting, using CRISPR technology, a mutant form of…

Novocure obtains OK by FDA to test novel pancreatic cancer treatment

New Jersey, US-based Novocure has obtained approval by FDA to initiate the Phase III PANOVA 3 clinical trial, aimed at assessing the efficacy of Tumor Treating Fields therapy in combination with nab-paclitaxel and gemcitabine in 556 patients with unresectable ,…

Review, adherence to treatment in type 2 diabetes

A systematic review of observational and interventional studies investigating adherence to treatment in patients with type 2 diabetes treated with hypoglicemizing agents has been published in the journal Diabetes, Obesity and Metabolism. Researchers from Surrey University, after assessing data from…

Sanofi’s Toujeo bests Tresiba in clinical trial with 929 patients

Sanofi has announced today that its insulin Toujeo has met the primary endpoint vs Novo Nordisk’s insulin Tresiba (degludec) in the Bright clinical trial.  Bright has been conducted on 829 patients with type II diabetes and its complete results will…

Excellent Phase III results for Teva’s chronic migraine therapy

The New England Journal of Medicine yesterday reported in a relevant article the results from the Phase III HALO trial, designed to assess the investigational drug fremanezumab, developed by Teva, on 1130 patients. The medicine, believed to be the most…

Antimicrobial resistance: new research opens way to block transmission

Some researchers at the Université de Montréal have investigated the antimicrobial resistance mechanisms to antibiotics and the new possible ways to prevent it. As already known, this issue is a worldwide healthcare emergency. Scientists have focused on transfer of plasmids,…

Coffee consumption: more benefits than risks

A research investigating the safety of everyday coffee drinking has been published in the The British Medical Journal. The researchers have analyzed over 200 studies and have concluded that drinking two or three cups per day – that is 400mg…

Can a genetic mutation protect from diabetes?

Results from a study establishing a link between a genetic mutation, a reduction in diabetes cases and lower glycaemia levels in fasting patients have been published on Science Advances. Some researchers at Northwestern University Feinberg School of Medicine, Chicago, have…

NASH, OK from Israel to test Oramed’s oral insulin

Oramed Pharmaceuticals, a biopharmaceutical company focusing on developing delivery solutions for oral drugs, has announced it has been granted an authorization by the Israeli regulatory authorities to conduct a clinical trial with its oral insulin ORMD-0801, in patients with NASH…

NEJM publishes Phase III results for Biogen/Ionis’ Spinraza

Biogen and Ionis Pharmaceuticals have announced that final results from the Phase III clinical trial ENDEAR, aimed at assessing Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA) have been published in the New England Journal of Medicine (NEJM)….

Novartis, Amgen and Banner Alzheimer’s Institute, cooperation broadened

Novartis, Amgen and Banner Alzheimer’s Institute (BAI) have announced they have broadened their cooperation. Specifically, the companies have informed they will initiate the API (Alzheimer’s Prevention Initiative) Generation Study 2, designed to assess the CNP520 BACE1 inhibitor in preventing or…

NASH: positive Phase II results for Gilead’s product

Gilead Science has announced the results from a Phase II randomized, placebo-controlled trial designed to assess GS-0976 in patients with NASH. The drug is an investigational oral product inhibiting ACC (Acetyl-CoA carboxylase). Two different dose regimens were tested in the…

New antibiotic therapies: what future?

The state of the art of new substances against bacterial infections has been checked at the IDWeek 2017, organized by the Infectious Disease Society of America (IDSA). One of the drugs recently approved by the FDA is the fixed-dose combination…

Alzheimer’s: Ionis Initiates phase I/II trial for antisense drug

Ionis Pharmaceuticals has initiated its Phase I//IIa clinical trial designed to test IONIS-MAPTRx in patients with moderate Alzheimer’s disease. Having initiated this study, Ionis will receive a $10m milestone payment from Biogen. IONIS-MAPTRx is an antisense drug designed to selectively…

Nocebo effect: new interesting research

According to a recent study, the perception and subsequent expectation of a prescribed drug’s side effects can create placebo or nocebo effect in patients. These effects are influenced by the drug’s price as well. In the study, researchers asked 49…

US NIH partners with 11 pharma groups to develop new immunotherapies

US NIH (National Institutes of Health) has entered into a cooperation agreement with 11 pharmaceutical companies in order to develop new biomarkers to advance new immunotherapies targeting cancer. The eleven companies that have signed the agreement include AbbVie, Roche, Bristol-Myers…